301 related articles for article (PubMed ID: 36347859)
1. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
[TBL] [Abstract][Full Text] [Related]
2. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
Ismail A; Shurrab FM; Al-Jighefee HT; Al-Sadeq DW; Qotba H; Al-Shaar IA; Yassine HM; Abu-Raddad LJ; Nasrallah GK
Front Biosci (Landmark Ed); 2021 Jul; 26(7):198-206. PubMed ID: 34340267
[No Abstract] [Full Text] [Related]
3. Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference.
Graninger M; Jani CM; Reuberger E; Prüger K; Gaspar P; Springer DN; Borsodi C; Weidner L; Rabady S; Puchhammer-Stöckl E; Jungbauer C; Höltl E; Aberle JH; Stiasny K; Weseslindtner L
Microbiol Spectr; 2023 Feb; 11(1):e0231422. PubMed ID: 36622205
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
5. Performance evaluation of four surrogate Virus Neutralization Tests (sVNTs) in comparison to the
Pieri M; Infantino M; Manfredi M; Nuccetelli M; Grossi V; Lari B; Tomassetti F; Sarubbi S; Russo E; Amedei A; Benucci M; Casprini P; Stacchini L; Castilletti C; Bernardini S
Front Biosci (Landmark Ed); 2022 Feb; 27(2):74. PubMed ID: 35227017
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera.
Ahn MJ; Kang JA; Hong SM; Lee KS; Kim DH; Song D; Jeong DG
Biochem Biophys Res Commun; 2023 Feb; 646():8-18. PubMed ID: 36696754
[TBL] [Abstract][Full Text] [Related]
8. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays.
Nandakumar V; Profaizer T; Lozier BK; Elgort MG; Larragoite ET; Williams ESCP; Solis-Leal A; Lopez JB; Berges BK; Planelles V; Rychert J; Slev PR; Delgado JC
Arch Pathol Lab Med; 2021 Oct; 145(10):1212-1220. PubMed ID: 34181714
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects.
Gillot C; Favresse J; Maloteau V; Dogné JM; Douxfils J
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835135
[TBL] [Abstract][Full Text] [Related]
11. Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern.
Santos da Silva E; Servais JY; Kohnen M; Arendt V; Staub T; The Con-Vince Consortium ; The CoVaLux Consortium ; Krüger R; Fagherazzi G; Wilmes P; Hübschen JM; Ollert M; Perez-Bercoff D; Seguin-Devaux C
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834413
[TBL] [Abstract][Full Text] [Related]
12. Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273.
Krüttgen A; Lauen M; Klingel H; Imöhl M; Kleines M
J Virol Methods; 2022 Jan; 299():114297. PubMed ID: 34563583
[TBL] [Abstract][Full Text] [Related]
13. Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies.
Lokida D; Karyana M; Kosasih H; Mardian Y; Sugiyono RI; Arlinda D; Lukman N; Salim G; Butar Butar DP; Naysilla AM; Irmansyah
Heliyon; 2022 Dec; 8(12):e12614. PubMed ID: 36575657
[TBL] [Abstract][Full Text] [Related]
14. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
[TBL] [Abstract][Full Text] [Related]
15. Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts.
Adams O; Andrée M; Hermsen D; Lübke N; Timm J; Schaal H; Müller L
J Virol Methods; 2022 Sep; 307():114569. PubMed ID: 35724697
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
[TBL] [Abstract][Full Text] [Related]
17. Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain.
Lee B; Ko JH; Lee KH; Kim YC; Song YG; Park YS; Baek YJ; Ahn JY; Choi JY; Song KH; Kim ES; Bae S; Kim SH; Jeong HW; Kim SW; Kwon KT; Kim SH; Jeong H; Kim B; Kim SS; Choi WS; Peck KR; Kang ES
Microbiol Spectr; 2022 Dec; 10(6):e0266922. PubMed ID: 36250875
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Valcourt EJ; Manguiat K; Robinson A; Chen JC; Dimitrova K; Philipson C; Lamoureux L; McLachlan E; Schiffman Z; Drebot MA; Wood H
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115294. PubMed ID: 33387896
[TBL] [Abstract][Full Text] [Related]
19. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.
Cristiano A; Nuccetelli M; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S
Int Immunopharmacol; 2021 Dec; 101(Pt B):108215. PubMed ID: 34649115
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT).
Winichakoon P; Wipasa J; Chawansuntati K; Salee P; Sudjaritruk T; Yasri S; Khamwan C; Peerakam R; Dankai D; Chaiwarith R
Sci Rep; 2023 Jan; 13(1):34. PubMed ID: 36593231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
